Clinical trial Recruiting at 3 sites Phase 2 Interventional Ages 18 to 45 Women only

FB301 for a Lactobacillus-dominant vaginal microbiome in a mock FET cycle

Official title: A Randomized, Double-blind, Three Arm, Multi-center Phase 2 Study to Investigate the Molecular Efficacy and Safety of FB301/Chlorhexidine Compared With FB301/Sham and Placebo/Sham in a Mock FET Cycle in Female Participants 18-45 Years of Age With Asymptomatic Vaginal Molecular Dysbiosis Planning to Undergo a Frozen Embryo Transfer (FET) Cycle

Run by Freya Biosciences ApS · NCT07453069 · Data updated 2026-11-12

This trial tests whether FB301 can help shift the vaginal bacteria toward Lactobacillus dominance in women with vaginal dysbiosis during a pretend embryo transfer cycle.

More Vaginal Dysbiosis trials

Quick facts

PhasePhase 2
Study typeInterventional
Ages18 Years to 45 Years
SexWomen only
Enrollment30 (estimated)
SponsorFreya Biosciences ApS
Industry-sponsored
Drugs / interventionschemotherapy
Locations4 sites (Wichita, Kansas and 3 other locations)
StatusRecruiting
StartedJuly 22, 2026
Main results expectedOctober 31, 2026
Study endsSeptember 30, 2027
Registry record updatedOctober 15, 2026
Trial IDNCT07453069 on ClinicalTrials.gov

Is this trial a fit for you?

Likely a good fit

Women aged 18–45 with a history of a prior failed FET and a molecularly defined vaginal dysbiosis who are planning a subsequent FET.

Probably not a fit

Individuals without Lactobacillus-dominant dysbiosis or those unlikely to pursue a subsequent FET may not benefit.

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This is a Phase 2, randomized, blind study evaluating FB301 versus placebo in premenopausal women with a prior failed FET and a defined vaginal dysbiosis. Participants receive a 15-day FB301 or placebo during a mock FET cycle after a vaginal cleansing, with a second arm using a chlorhexidine cleanse before FB301. The primary outcome is the proportion of participants achieving a Lactobacillus-dominant vaginal microbiome after therapy. Secondary aims include pregnancy-related biochemical outcomes and safety/tolerability in the context of a simulated embryo transfer process. The study will monitor participants through the mock cycle and, if appropriate, into a subsequent actual FET cycle.

Why it matters

Potential benefit: If successful, FB301 could help promote a healthier vaginal microbiome that may improve chances in future embryo transfer attempts.

How similar studies have gone: Previous research has linked Lactobacillus-dominant vaginal profiles with better reproductive outcomes in FET, supporting exploration of microbiome-modifying therapies.

Who can join: the full rules

Show full inclusion / exclusion criteria
Inclusion Criteria:

1. Able to understand the study and sign a consent form.
2. Is a woman aged 18 to 45 years.
3. Still has regular menstrual periods (pre-menopausal).
4. Has had at least one previous frozen embryo transfer (FET) that did not result in pregnancy within the past 3 years, and this was not due to either male infertility or blocked /damaged fallopian tubes.
5. Willing to take part in mock frozen embryo transfer (FET) cycle and is considered medically suitable to subsequently have a frozen embryo transfer (FET) using one good-quality embryo (grade 3BB or higher).
6. Willing to have only one embryo transferred during the study cycle.
7. A vaginal swab taken at the first study visit shows a specific vaginal microbiome imbalance required for this study (vaginal molecular dysbiosis).
8. An ultrasound scan shows no problems with uterus or pelvis that would prevent pregnancy or greatly reduce the chance of pregnancy.
9. Recent fertility blood tests show FSH less than 12 IU/L (within the last 6 months)
10. Recent fertility blood tests show AMH greater than 1 ng/mL (at the time of oocyte retrieval).
11. Body mass index (BMI) is between 18 and 42 kg/m².
12. From the first study treatment until the mock FET cycle, agrees to:

    * Avoid vaginal intercourse or use condoms (without spermicide or lubricant),
    * Avoid swimming or hot tubs,
    * Avoid using tampons, menstrual cups, sex toys, vaginal cleansers, lubricants, or other vaginal products unless approved by the study team.
13. Willing to answer questions about sexual and reproductive activity during the study.
14. Willing to provide vaginal swab samples at the clinic.
15. Willing to receive the first study treatment in the clinic and use the study treatment at home as instructed.
16. Screening blood tests are negative for hepatitis B, hepatitis C, HIV, and syphilis.
17. Willing to attend all study visits and follow-up assessments and provide information about pregnancy and newborn health outcomes.

Exclusion Criteria:

1. History of five or more failed frozen embryo transfers (FET) in the past 5 years.
2. Have a condition that weakens the immune system (such as uncontrolled diabetes, active cancer, or an organ transplant).
3. Currently taking medications that suppress the immune system (such as systemic steroids, biologics, chemotherapy, or transplant medications).
4. Is already pregnant before completing the mock FET cycle.
5. Test positive for a sexually transmitted infection (such as chlamydia, gonorrhea, Mycoplasma genitalium, or Trichomonas vaginalis).
6. Current vaginal yeast infection that requires treatment.
7. Cannot safely take the hormone medications required for a frozen embryo transfer (such as estradiol or progesterone).
8. Use of intravaginal progesterone gels or solutions.
9. Needs regular antibiotics or are likely to require antibiotics during the study.
10. Has taken oral, injectable, or vaginal antibiotics within 30 days before screening.
11. History of gynecological cancer or other significant gynecological condition that would make participation unsafe.
12. Has a medical condition that would make participation unsafe or difficult.
13. Has an unstable medical or psychiatric condition that could make it difficult to follow study requirements.
14. Has any other condition that could interfere with participation.

Where it's running

  • Cypress Medical Research Centre
    Wichita, Kansas, United States
    Recruiting
  • REACH Fertility
    Charlotte, North Carolina, United States
    Recruiting
  • Delta Hy Research LLC / Advanced Fertility Texas
    Houston, Texas, United States
    Recruiting
  • Boston IVF
    Waltham, Massachusetts, United States
    Not yet recruiting

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

How to take part

  1. Review the eligibility criteria above with your treating physician.
  2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
  3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.
Last reviewed 2026-11-14 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.